Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
2.700
-0.100 (-3.57%)
At close: Oct 26, 2026, 4:00 PM EDT
2.700
0.00 (0.00%)
After-hours: Oct 26, 2026, 4:10 PM EDT
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
221.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| AC Immune | 21.67M |
| Keros Therapeutics | 15.01M |
| Sol-Gel Technologies | 1.80M |
| Palisade Bio | 500.00K |
| Lyell Immunopharma | 27.00K |
| InflaRx | -11.54K |
LXEO News
- 5 days ago - Lexeo Therapeutics Transcript: Investor update - Transcripts
- 6 days ago - Lexeo Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 7 days ago - Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM - GlobeNewsWire
- 18 days ago - Lexeo Therapeutics to Participate in the Chardan Healthcare Conference - GlobeNewsWire
- 25 days ago - Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) - GlobeNewsWire
- 26 days ago - Lexeo Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts
- 4 weeks ago - Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia - PRNewsWire
- 4 weeks ago - Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewsWire